LTR Pharma Limited (AU:LTP) has released an update.
LTR Pharma Limited is set to hold its Annual General Meeting on 27 November 2024 in Brisbane, where shareholders will have the chance to discuss the company’s innovative nasal spray for Erectile Dysfunction, SPONTAN®. This product is unique due to its rapid intranasal delivery, promising quick results for users, highlighting LTR Pharma’s commitment to improving men’s health.
For further insights into AU:LTP stock, check out TipRanks’ Stock Analysis page.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
